IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma

Trial Profile

IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms IFM 2014-02
  • Most Recent Events

    • 18 Aug 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Sep 2019 to 1 Jan 2020.
    • 18 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 31 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top